Bulbocapnine (Aporphine Alkaloid · Vestibular Suppression · Dopaminergic)

Compound	Bulbocapnine
Chemical class	Alkaloid — Isoquinoline (Aporphine)
CAS	298-45-3
Primary source	Corydalis spp., Fumaria officinalis (fumitory), Dicentra spp.
Key applications	Dopaminergic modulation, vestibular suppression, tremor research
Claim strength	Moderate
Typical form	Fumitory extract co-constituent; Corydalis extract
Buy from Herbuno	Fumitory Extract Powder - Fumaria Officinalis →

Commercial source: Bulbocapnine is commercially available as a co-constituent of Fumaria officinalis extract, alongside protopine and other fumitory alkaloids. It is also present in Corydalis species. Isolated bulbocapnine is available as a research-grade material from specialist chemical suppliers. See sourcing options below. Traditional use: Fumitory has traditional use in European, Arabic, and Ayurvedic medicine for biliary and digestive complaints (covered under protopine’s entry). Bulbocapnine’s individual vestibular-suppressing and tremor-reducing properties were not recognised in traditional practice. Research trajectory: Bulbocapnine was historically significant as one of the first botanically-derived compounds used clinically for vestibular disorders and Parkinson’s tremor (in pre-levodopa era medicine). It is an aporphine alkaloid — a structurally distinct class from tetrahydroprotoberberines and quaternary protoberberines. Its pharmacology involves dopamine D2 receptor partial agonism/antagonism and sigma receptor binding, producing unique CNS effects. See sourcing options below.

---

Evidence for Bulbocapnine Applications

Vestibular suppression and motion sickness: Bulbocapnine was used in pre-pharmaceutical medicine for labyrinthine nystagmus (vestibular imbalance) and tremor, administered as a Corydalis/Fumaria alkaloid preparation. Modern pharmacological studies confirm its vestibular suppressing activity via dopamine receptor modulation in the brainstem vestibular nuclei. Relevant historical context for vertigo and motion sickness formulation research. Claim strength: Moderate (historical clinical use documented; modern RCT evidence absent).

Dopaminergic modulation and tremor: Bulbocapnine reduces tremor in animal models of Parkinson’s disease and essential tremor via dopamine D2 receptor interactions in the substantia nigra. It was used in the pre-levodopa era as a botanical tremor management agent. This application is primarily of historical pharmacological interest. Claim strength: Moderate.

Sigma receptor binding: Bulbocapnine has high affinity for sigma-1 and sigma-2 receptors, which are implicated in neuroprotection, cognitive function, and cell survival pathways. Sigma receptor research is an active area; bulbocapnine is a useful pharmacological tool compound for this target class. Claim strength: Emerging (mechanism relevant; therapeutic translation unstudied).

---

Dosage & Formulator Specification

Bulbocapnine is not formulated as a standalone contemporary supplement ingredient. Historical pharmaceutical use involved injectable preparations at doses far exceeding what botanical extract delivery achieves. At typical fumitory extract doses (150–300 mg/day), bulbocapnine co-delivery is minimal (<2–5 mg). Isolated bulbocapnine is available from specialist chemical suppliers for research purposes. Its primary modern relevance is as a pharmacological research tool compound rather than a commercial supplement active.

---

Frequently Asked Questions — Bulbocapnine

Is bulbocapnine related to morphine pharmacologically?
No. Despite both being isoquinoline alkaloids found in the Papaveraceae family, bulbocapnine and morphine are structurally and pharmacologically distinct. Bulbocapnine is an aporphine alkaloid (dopaminergic, sigma receptor active); morphine is a morphinan alkaloid (opioid receptor agonist). They do not share receptor interactions or clinical pharmacological profiles.

Why was bulbocapnine used in pre-levodopa Parkinson’s management?
Before levodopa was developed (1960s), Parkinson’s tremor management used various anticholinergic and dopaminergic botanical alkaloids. Bulbocapnine’s dopamine D2 receptor interactions reduced tremor modestly in clinical practice. It was eventually displaced by more effective synthetic dopaminergic agents and levodopa itself. Its historical clinical use is valuable context for understanding the botanical pharmacology of the aporphine alkaloid class.

Is bulbocapnine still used in any clinical context?
Bulbocapnine is not a current pharmaceutical agent in any major market. It is a historical botanical pharmaceutical and a contemporary research tool compound for dopaminergic and sigma receptor pharmacology. No supplement product markets it as a primary active ingredient in Western markets. Its presence in fumitory and Corydalis extract is incidental to those extracts’ primary clinical applications.

Is fumitory extract safe given its bulbocapnine content?
At typical fumitory supplement doses, bulbocapnine content is very low and pharmacologically sub-therapeutic for the vestibular or tremor-reducing effects. Fumitory’s primary clinical safety concern centres on protopine and its antispasmodic profile, not bulbocapnine. Standard fumitory extract safety guidance (short-term use, liver condition advisory) applies and is not related to bulbocapnine pharmacology at supplement doses.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery